The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

Recruiting now · Phase 3

Conditions studied: COPD

In brief

This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators

Key facts

Study ID

NCT06474039

Run by

Mahidol University

People needed

50

Starts

2024-10-01

Expected to finish

2026-12-01

Last updated by the study team

2025-05-06

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence.
• Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators
• Patients who are able to provide informed consent.

You may not qualify if…

• - Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases.
• Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids
• Being treated with triple therapy (ICS/LABA/LAMA)
• Being in terminally ill conditions

Where it is running

• Division of Respiratory Disease and TB, Siriraj Hospital — Bangkoknoi, BKK, Thailand (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.